Related Experiment Video
Updated: Aug 9, 2026
In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer
Published on: August 17, 2010
Structure-based virtual screening identified novel FOXM1 inhibitors as the lead compounds for ovarian cancer
Zi-Ying Zhou1, Xiao-Yang Han1, Lian-Qi Sun1
1Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Abstract:
Ovarian cancer (OC) is a gynecological tumor with possibly the worst prognosis, its 5-year survival rate being only 47.4%. The first line of therapy prescribed is chemotherapy consisting of platinum and paclitaxel. The primary reason for treatment failure is drug resistance. FOXM1 protein has been found to be closely associated with drug resistance, and inhibition of FOXM1 expression sensitizes cisplatin-resistant ovarian cancer cells. Combining existing first-line chemotherapy drugs with FOXM1 prolongs the overall survival of patients, therefore, FOXM1 is considered a potential therapeutic target in ovarian cancer. Previous research conducted by our team revealed a highly credible conformation of FOXM1 which enables binding by small molecules. Based on this conformation, the current study conducted virtual screening to determine a new structural skeleton for FOXM1 inhibitors which would enhance their medicinal properties. DZY-4 showed the highest affinity towards FOXM1, and its inhibitory effect on proliferation and migration of ovarian cancer at the cellular level was better than or equal to that of cisplatin, while its efficacy was equivalent to that of cisplatin in a nude mouse model. In this study, the anti-tumor effect of DZY-4 is reported for the first time. DZY-4 shows potential as a drug that can be used for ovarian cancer treatment, as well as a drug lead for future research.
Insights
Researchers identified DZY-4, a novel compound targeting FOXM1, to combat drug-resistant ovarian cancer. This new drug candidate shows significant potential for improving patient survival rates in preclinical studies.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Ovarian cancer (OC) has a poor prognosis, with a 5-year survival rate of 47.4%.
- Chemotherapy resistance is a major challenge in OC treatment.
- FOXM1 protein is implicated in drug resistance and is a potential therapeutic target.
Purpose of the Study:
- To identify novel FOXM1 inhibitors for ovarian cancer treatment.
- To evaluate the anti-tumor efficacy of a new compound, DZY-4.
- To explore DZY-4 as a potential drug lead for ovarian cancer.
Main Methods:
- Virtual screening was employed to identify small molecule inhibitors targeting FOXM1.
- The inhibitory effects of DZY-4 on ovarian cancer cell proliferation and migration were assessed.
- The efficacy of DZY-4 was evaluated in a nude mouse model.
Main Results:
- DZY-4 demonstrated high affinity for FOXM1.
- DZY-4 exhibited potent inhibition of ovarian cancer cell proliferation and migration.
- In vivo studies showed DZY-4's efficacy was comparable to cisplatin in a nude mouse model.
Conclusions:
- DZY-4 is a novel FOXM1 inhibitor with significant anti-tumor activity against ovarian cancer.
- DZY-4 shows promise as a potential therapeutic agent for ovarian cancer.
- DZY-4 serves as a valuable drug lead for future ovarian cancer research.
